Madrigal Pharmaceuticals Inc (MDGL) Forecasted to Post Q1 2019 Earnings of ($0.90) Per Share

Share on StockTwits

Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) – Stock analysts at Svb Leerink cut their Q1 2019 earnings estimates for Madrigal Pharmaceuticals in a research note issued to investors on Monday, March 11th. Svb Leerink analyst P. Sarraf now anticipates that the biopharmaceutical company will post earnings of ($0.90) per share for the quarter, down from their prior estimate of ($0.87). Svb Leerink has a “Outperform” rating and a $165.00 price target on the stock. Svb Leerink also issued estimates for Madrigal Pharmaceuticals’ Q2 2019 earnings at ($1.03) EPS, Q3 2019 earnings at ($1.17) EPS, Q4 2019 earnings at ($1.33) EPS, FY2019 earnings at ($4.44) EPS, Q1 2020 earnings at ($1.17) EPS, Q2 2020 earnings at ($1.24) EPS, Q3 2020 earnings at ($1.36) EPS, Q4 2020 earnings at ($1.40) EPS, FY2020 earnings at ($5.22) EPS, FY2021 earnings at ($6.39) EPS, FY2022 earnings at ($8.06) EPS and FY2023 earnings at ($4.31) EPS.

MDGL has been the subject of a number of other research reports. ValuEngine downgraded shares of Madrigal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, January 30th. Zacks Investment Research upgraded shares of Madrigal Pharmaceuticals from a “hold” rating to a “buy” rating and set a $133.00 price objective for the company in a report on Wednesday, January 9th. Evercore ISI upgraded shares of Madrigal Pharmaceuticals from an “in-line” rating to an “outperform” rating and increased their price objective for the company from $222.00 to $250.00 in a report on Friday, November 16th. HC Wainwright reiterated a “buy” rating and issued a $313.00 price objective on shares of Madrigal Pharmaceuticals in a report on Wednesday, December 12th. Finally, UBS Group initiated coverage on shares of Madrigal Pharmaceuticals in a research note on Wednesday, January 23rd. They issued a “neutral” rating and a $119.00 price target for the company. Two investment analysts have rated the stock with a sell rating, four have given a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $221.18.

MDGL stock opened at $138.41 on Thursday. The stock has a market capitalization of $2.13 billion, a price-to-earnings ratio of -62.35 and a beta of 1.21. Madrigal Pharmaceuticals has a 12 month low of $91.56 and a 12 month high of $325.98.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its quarterly earnings data on Wednesday, February 27th. The biopharmaceutical company reported ($0.75) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.74) by ($0.01). During the same quarter in the prior year, the business posted ($0.67) EPS.

Several institutional investors have recently bought and sold shares of MDGL. Pearl River Capital LLC purchased a new stake in shares of Madrigal Pharmaceuticals in the 4th quarter valued at approximately $29,000. First Mercantile Trust Co. grew its stake in shares of Madrigal Pharmaceuticals by 52.2% in the 4th quarter. First Mercantile Trust Co. now owns 624 shares of the biopharmaceutical company’s stock valued at $70,000 after buying an additional 214 shares during the period. Quantamental Technologies LLC purchased a new position in shares of Madrigal Pharmaceuticals during the 4th quarter worth approximately $90,000. Great West Life Assurance Co. Can boosted its position in shares of Madrigal Pharmaceuticals by 59.1% during the 4th quarter. Great West Life Assurance Co. Can now owns 985 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 366 shares during the period. Finally, Bessemer Group Inc. purchased a new position in shares of Madrigal Pharmaceuticals during the 4th quarter worth approximately $116,000. 59.06% of the stock is owned by institutional investors and hedge funds.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia.

Featured Story: Bollinger Bands

Earnings History and Estimates for Madrigal Pharmaceuticals (NASDAQ:MDGL)

Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

HomeBlockCoin  Price Tops $0.0005 on Exchanges
HomeBlockCoin Price Tops $0.0005 on Exchanges
Vale SA  Shares Sold by Schafer Cullen Capital Management Inc
Vale SA Shares Sold by Schafer Cullen Capital Management Inc
Key Square Capital Management LLC Sells 54,202 Shares of Telecom Argentina SA
Key Square Capital Management LLC Sells 54,202 Shares of Telecom Argentina SA
643,861 Shares in Emerge Energy Services LP  Purchased by HPS Investment Partners LLC
643,861 Shares in Emerge Energy Services LP Purchased by HPS Investment Partners LLC
Family Legacy Inc. Raises Stake in Chubb Ltd
Family Legacy Inc. Raises Stake in Chubb Ltd
MESSE TOKEN Price Down 0.4% This Week
MESSE TOKEN Price Down 0.4% This Week


Leave a Reply

© 2006-2019 Ticker Report